ASH 2023 | MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, introduces a Phase I/IIa study (NCT05673057) of MP0533, a CD3-engaging DARPin (Designed Ankyrin Repeat Protein) which targets CD33, CD123, and CD70 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Honoraria: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Research Funding: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Seagen, Takeda, Molecular Partners
Speakers Bureau: Janssen, Roche, BMS/Celgene, Novartis, Gilead/Kite, Pfizer, AstraZeneca, GSK, LAWG, Springer Healthcare
Travel Support: Roche, Gilead/Kite, Pfizer
